MX2019007801A - Tratamiento de cáncer avanzado con expresión de her2. - Google Patents
Tratamiento de cáncer avanzado con expresión de her2.Info
- Publication number
- MX2019007801A MX2019007801A MX2019007801A MX2019007801A MX2019007801A MX 2019007801 A MX2019007801 A MX 2019007801A MX 2019007801 A MX2019007801 A MX 2019007801A MX 2019007801 A MX2019007801 A MX 2019007801A MX 2019007801 A MX2019007801 A MX 2019007801A
- Authority
- MX
- Mexico
- Prior art keywords
- her2
- treatment
- cancer
- advanced
- amplified
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se describen métodos para el tratamiento de pacientes con cáncer avanzado HER2 positivo, HER2 amplificado y/o HER2 mutado mediante la administración de pertuzumab más trastuzumab. En un aspecto, el cáncer es cáncer avanzado HER2 positivo, HER2 amplificado y/o HER2 mutado colorrectal, biliar, vesical, urotelial, salival, de pulmón, pancreático, de ovario, de próstata o de piel. En otro aspecto, el cáncer es cáncer avanzado HER2 positivo, HER2 amplificado y/o HER2 mutado colorrectal, biliar, vesical, urotelial, salival, de pulmón, pancreático, de ovario, de próstata o de piel que es refractario a uno o más regímenes de tratamiento.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662439815P | 2016-12-28 | 2016-12-28 | |
| US201762457672P | 2017-02-10 | 2017-02-10 | |
| US201762519599P | 2017-06-14 | 2017-06-14 | |
| PCT/US2017/066286 WO2018125589A1 (en) | 2016-12-28 | 2017-12-14 | Treatment of advanced her2 expressing cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019007801A true MX2019007801A (es) | 2019-10-30 |
Family
ID=60957441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019007801A MX2019007801A (es) | 2016-12-28 | 2017-12-14 | Tratamiento de cáncer avanzado con expresión de her2. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20180221481A1 (es) |
| EP (1) | EP3562844A1 (es) |
| JP (2) | JP6914336B2 (es) |
| KR (1) | KR102313262B1 (es) |
| CN (1) | CN110099926A (es) |
| AU (2) | AU2017387909A1 (es) |
| CA (1) | CA3046092A1 (es) |
| IL (1) | IL267675A (es) |
| MX (1) | MX2019007801A (es) |
| TW (1) | TW201827077A (es) |
| WO (1) | WO2018125589A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| DK3570884T3 (da) | 2017-01-17 | 2020-11-30 | Genentech Inc | Subkutane HER2-antistofformuleringer |
| CN116850283A (zh) | 2017-03-02 | 2023-10-10 | 豪夫迈·罗氏有限公司 | Her2阳性乳腺癌的辅助治疗 |
| WO2019241599A1 (en) * | 2018-06-14 | 2019-12-19 | Memorial Sloan Kettering Cancer Center | Methods for predicting responsiveness of lung cancer patients to her2-targeting therapies |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4933294A (en) | 1984-01-30 | 1990-06-12 | Icrf Patents Limited | Method of detecting truncated epidermal growth factor receptors |
| US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
| US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
| US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| DK0474727T3 (da) | 1989-05-19 | 1998-01-12 | Genentech Inc | HER2 ekstracellulært domæne |
| WO1991005264A1 (en) | 1989-09-29 | 1991-04-18 | Oncogenetics Partners | Detection and quantification of neu related proteins in the biological fluids of humans |
| US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| EP0861893A3 (en) | 1991-09-19 | 1999-11-10 | Genentech, Inc. | High level expression of immunoglobulin polypeptides |
| PT1516628E (pt) | 1995-07-27 | 2013-09-24 | Genentech Inc | Formulação de proteína liofilizada isotónica estável |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US7371376B1 (en) | 1996-10-18 | 2008-05-13 | Genentech, Inc. | Anti-ErbB2 antibodies |
| EP1900751B1 (en) | 1996-11-27 | 2009-12-09 | Genentech, Inc. | Affinity purification of polypeptide on protein a matrix |
| US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| ATE398464T1 (de) | 1998-03-27 | 2008-07-15 | Genentech Inc | Synergie zwischen apo-2 ligand und antikörper gegen her-2 |
| ES2261589T3 (es) | 1998-05-06 | 2006-11-16 | Genentech, Inc. | Composicion de anticuerpos anti-her2. |
| US6573043B1 (en) | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
| JP5623681B2 (ja) | 1999-05-14 | 2014-11-12 | ジェネンテック， インコーポレイテッド | 抗−ＥｒｂＢ２抗体による治療 |
| KR100754049B1 (ko) | 1999-06-25 | 2007-08-31 | 제넨테크, 인크. | 전립선암을 치료하기 위한 약제 제조에 사용되는 항-ErbB2 항체 및 조성물 |
| US20030086924A1 (en) | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| US20040013667A1 (en) | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| US6754305B1 (en) | 1999-08-02 | 2004-06-22 | Therma-Wave, Inc. | Measurement of thin films and barrier layers on patterned wafers with X-ray reflectometry |
| US6627196B1 (en) | 1999-08-27 | 2003-09-30 | Genentech, Inc. | Dosages for treatment with anti-ErbB2 antibodies |
| US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| US6632979B2 (en) | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
| KR20130056201A (ko) | 2000-05-19 | 2013-05-29 | 제넨테크, 인크. | ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석 |
| US6984494B2 (en) | 2000-08-15 | 2006-01-10 | Genentech, Inc. | Analytical method |
| KR20100031769A (ko) | 2000-12-28 | 2010-03-24 | 알투스 파마슈티컬스 인코포레이티드 | 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법 |
| US6695940B2 (en) | 2001-04-05 | 2004-02-24 | Alan D. Devoe | Laminate thin-wall ceramic tubes, including with integral stress wrappings, thickened ends and/or internal baffles, particularly for solid oxide fuel cells |
| US20040048525A1 (en) | 2002-01-28 | 2004-03-11 | Sagucio Esteban N. | Watercycle for wet rider |
| DK1501856T3 (da) | 2002-04-10 | 2013-03-25 | Genentech Inc | Anti-HER2 antistofvarianter |
| CN102295703A (zh) | 2002-07-15 | 2011-12-28 | 健泰科生物技术公司 | 鉴定对用抗ErbB2抗体处理响应的肿瘤的方法 |
| US6982719B2 (en) | 2002-07-15 | 2006-01-03 | Sun Microsystems, Inc. | Switching sample buffer context in response to sample requests for real-time sample filtering and video generation |
| US7129840B2 (en) | 2002-09-03 | 2006-10-31 | Ricoh Company, Ltd. | Document security system |
| CA2506320A1 (en) | 2002-11-21 | 2004-06-10 | Genentech, Inc. | Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies |
| EP3722309A1 (en) | 2003-07-28 | 2020-10-14 | Genentech, Inc. | Reducing protein a leaching during protein a affinity chromatography |
| CA2563341C (en) | 2004-04-08 | 2014-10-21 | David B. Agus | Erbb antagonists for pain therapy |
| US7195440B2 (en) | 2004-05-27 | 2007-03-27 | Lambert Charles F | Agricultural silo auger system apparatus and method |
| JP5234734B2 (ja) | 2004-06-01 | 2013-07-10 | ジェネンテック， インコーポレイテッド | 抗体−薬物結合体および方法 |
| SV2006002143A (es) | 2004-06-16 | 2006-01-26 | Genentech Inc | Uso de un anticuerpo para el tratamiento del cancer resistente al platino |
| UA90480C2 (uk) | 2004-07-22 | 2010-05-11 | Джэнэнтэк, Инк. | Фармацевтична композиція, що має протипухлинну активність, яка включає антитіло до her2 |
| JP2008510466A (ja) | 2004-08-19 | 2008-04-10 | ジェネンテック・インコーポレーテッド | エフェクター機能が変更しているポリペプチド変異体 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| CA2587519A1 (en) | 2004-12-07 | 2006-06-15 | Genentech, Inc. | Selecting patients for therapy with a her inhibitor |
| AU2005325200A1 (en) | 2005-01-21 | 2006-07-27 | Genentech, Inc. | Fixed dosing of HER antibodies |
| JP2008531576A (ja) | 2005-02-23 | 2008-08-14 | ジェネンテック・インコーポレーテッド | Ｈｅｒ二量体化阻害剤を使用した、ガン患者における疾患の進行までの期間または生存の延長 |
| TW200642695A (en) | 2005-03-08 | 2006-12-16 | Genentech Inc | Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs) |
| US20060212956A1 (en) | 2005-03-14 | 2006-09-21 | Genentech, Inc. | Animal model of ligand activated HER2 expressing tumors |
| JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| US20070009976A1 (en) | 2005-07-06 | 2007-01-11 | Helmut Lenz | Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody |
| PE20070207A1 (es) | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| US7700299B2 (en) | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
| EP1971367A4 (en) | 2005-12-05 | 2010-04-07 | Trinity Biosystems Inc | METHOD AND COMPOSITIONS FOR THE NEEDLESS DELIVERY OF BINDING PARTNERS |
| WO2007076923A1 (en) * | 2006-01-04 | 2007-07-12 | Merck Patent Gmbh | Combination therapy using anti-egfr and anti-her2 antibodies |
| TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
| CA2654584A1 (en) | 2006-06-05 | 2007-12-21 | Genentech, Inc. | Extending survival of cancer patients with elevated levels of egf or tgf-alpha |
| BRPI0715829A2 (pt) | 2006-08-21 | 2013-07-23 | Hoffmann La Roche | terapia de tumor com um anticorpo anti-vegf |
| WO2008031531A1 (en) * | 2006-09-15 | 2008-03-20 | F. Hoffmann-La Roche Ag | Tumor therapy with a combination of anti-her2 antibodies |
| NZ578824A (en) | 2007-03-02 | 2012-03-30 | Genentech Inc | Predicting response to a her dimerisation inhibitor based on low her3 expression |
| JP5373776B2 (ja) | 2007-06-06 | 2013-12-18 | エフ．ホフマン−ラ ロシュ アーゲー | 腫瘍抗原に結合する無標識一次モノクローナル抗体と、ｎｉｒフルオレセイン標識で標識された非交差反応性二次モノクローナル抗体から成る組成物 |
| US20100298156A1 (en) | 2007-06-08 | 2010-11-25 | Si Tuen Lee-Hoeflich | Gene expression markers of tumor resistance to her2 inhibitor treatment |
| CL2008002687A1 (es) | 2007-09-12 | 2009-01-16 | Genentech Inc | Uso de una combinacion farmaceutica de un compuesto derivado de tieno[3,2-d]pirimidina con un agente quimioterapeutico en el tratamiento de un trastorno hiperproliferativo; kit farmaceutico. |
| ES2666170T3 (es) | 2007-10-30 | 2018-05-03 | Genentech, Inc. | Purificación de anticuerpos mediante cromatografía de intercambio catiónico |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| US20090226455A1 (en) | 2008-03-06 | 2009-09-10 | Genentech, Inc. | Combination therapy with c-met and her antagonists |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| AU2012258087B2 (en) * | 2011-05-13 | 2017-07-20 | Astellas Pharma Inc. | Antibodies for treatment of cancer expressing claudin 6 |
| PE20142363A1 (es) * | 2011-10-14 | 2015-01-30 | Genentech Inc | Usos y articulo de fabricacion que incluye el inhibidor de la dimerizacion de her2 pertuzumab |
| AU2014254086B2 (en) * | 2013-04-16 | 2018-07-05 | Genentech, Inc. | Pertuzumab variants and evaluation thereof |
| EP3581586A1 (en) * | 2014-04-25 | 2019-12-18 | F. Hoffmann-La Roche AG | Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab |
| WO2016201454A1 (en) * | 2015-06-12 | 2016-12-15 | The Translational Genomics Research Institute | Targeted therapies for cancer |
-
2017
- 2017-12-14 CA CA3046092A patent/CA3046092A1/en not_active Abandoned
- 2017-12-14 TW TW106143867A patent/TW201827077A/zh unknown
- 2017-12-14 US US15/842,726 patent/US20180221481A1/en not_active Abandoned
- 2017-12-14 KR KR1020197020412A patent/KR102313262B1/ko active IP Right Grant
- 2017-12-14 MX MX2019007801A patent/MX2019007801A/es unknown
- 2017-12-14 CN CN201780080251.7A patent/CN110099926A/zh active Pending
- 2017-12-14 JP JP2019534843A patent/JP6914336B2/ja active Active
- 2017-12-14 EP EP17829076.3A patent/EP3562844A1/en not_active Withdrawn
- 2017-12-14 AU AU2017387909A patent/AU2017387909A1/en not_active Abandoned
- 2017-12-14 WO PCT/US2017/066286 patent/WO2018125589A1/en unknown
-
2019
- 2019-06-26 IL IL267675A patent/IL267675A/en unknown
-
2020
- 2020-03-24 US US16/828,045 patent/US20200237910A1/en not_active Abandoned
-
2021
- 2021-03-10 AU AU2021201516A patent/AU2021201516A1/en not_active Abandoned
- 2021-07-13 JP JP2021115575A patent/JP7234303B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20200237910A1 (en) | 2020-07-30 |
| IL267675A (en) | 2019-08-29 |
| JP2021178832A (ja) | 2021-11-18 |
| CA3046092A1 (en) | 2018-07-05 |
| EP3562844A1 (en) | 2019-11-06 |
| AU2021201516A1 (en) | 2021-04-01 |
| KR102313262B1 (ko) | 2021-10-14 |
| US20180221481A1 (en) | 2018-08-09 |
| JP2020514281A (ja) | 2020-05-21 |
| TW201827077A (zh) | 2018-08-01 |
| AU2017387909A1 (en) | 2019-06-27 |
| KR20190094228A (ko) | 2019-08-12 |
| CN110099926A (zh) | 2019-08-06 |
| JP7234303B2 (ja) | 2023-03-07 |
| WO2018125589A1 (en) | 2018-07-05 |
| JP6914336B2 (ja) | 2021-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019007801A (es) | Tratamiento de cáncer avanzado con expresión de her2. | |
| MX2018008426A (es) | Combinaciones anti-egfr para tratar tumores. | |
| MX2020008977A (es) | Formulaciones de anticuerpos de her2 subcutaneas. | |
| MX2021004881A (es) | Combinacion de palbociclib y rad1901 para usarse en el tratamiento de cancer de mama en un sujeto con cancer positivo a receptor de estrogeno. | |
| MA39906A (fr) | Polythérapies pour le traitement du cancer | |
| PH12018500380A1 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
| MY190034A (en) | Method of treating cancer associated with a ras mutation | |
| MX2019003780A (es) | Uso de la combinación de anticuerpo anti-pd-1 e inhibidor de vegfr en la preparación de medicamentos para el tratamiento de cánceres. | |
| MX2016014007A (es) | Metodos para el tratamiento de cancer de mama temprano con trastuzumab-emtansina(mcc-dm1) y pertuzumab. | |
| GEP20217317B (en) | Combination therapy for the treatment of cancer | |
| EA201992251A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
| MX2022008523A (es) | Compuestos que interactuan con glicanos y metodos de uso. | |
| MX2013006392A (es) | Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1. | |
| DK2766040T3 (da) | Pertuzumab, trastuzumab, docetaxel og carboplatin til behandling af brystkræft i et tidligt stadie | |
| PH12019500135A1 (en) | Methods of treating prostate cancer | |
| MX2019006331A (es) | Métodos para tratar el cáncer usando anticuerpos anti-pd-l1 y antiandrógenos. | |
| MX2017006015A (es) | Composiciones para usar en el tratamiento de cancer renal. | |
| MX2018006249A (es) | Nuevos anticuerpos anti-emr2 y metodos de uso. | |
| MX2020010269A (es) | Un anticuerpo anti-il-23p 19 (mirikizumab) para usarse en el tratamiento de la colitis ulcerosa. | |
| MX2017006026A (es) | Apilimod para uso en el tratamiento de cancer colorrectal. | |
| MX2020008613A (es) | Conjugados de anticuerpo anti-factor tisular-farmaco y su uso en el tratamiento de cancer. | |
| MX2019004804A (es) | Tratamiento para el prurigo nodula. | |
| MX2018007817A (es) | Nuevos anticuerpos anti-mmp16 y metodos para su uso. | |
| MX2023007680A (es) | Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina. | |
| EP4061846A4 (en) | METHODS OF TREATING CANCER USING ANTI-OX40 ANTIBODIES IN COMBINATION WITH ANTI-TIGIT ANTIBODIES |